## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| C. 20549 |
|----------|
|          |

| STATEMENT | OF CHAN | NGES IN BE | NEFICIAL ( | OWNERSHIP |
|-----------|---------|------------|------------|-----------|

| OMB APPRO                | )VAL      |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>LIDDY EDWARD M</u> |  |                                      |   | 2. Issuer Name <b>and</b> Ticker or Trading Symbol AbbVie Inc. [ ABBV ] |   |      |                   |        |                    |  |                       | Relationship<br>theck all app  | icable)<br>or                          | g Pers  | 10% Ov   | vner   |           |  |
|--|--|--------------------------------------|---|---|---|------|-------------------|--------|--------------------|--|-----------------------|--|--|---|--|--|-----------|--|
| (Last) (First) (Middle) 1 N. WAUKEGAN ROAD                     |  |                                      |   |   | 3. Date of Earliest Transaction (Month/Day/Year) 12/31/2014 |      |                   |        |                    |  |                       |  | Office<br>below                        | r (give title<br>')                                 |  | Other (s<br>below)                             | specify   |  |
| (Street) NORTH CHICAC  |  |                                      | 50064<br>Zip)   |   | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |      |                   |        |                    |  |                       | Individual or Joint/Group Filing (Check Applicable lee)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |  |   |  | n  |           |  |
|  | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |                                      |   |   |   |      |                   |        |                    |  |                       |  |  |   |  |  |           |  |
| 1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)  |  |                                      |   | Execution Date,   |   |      | Code (Instr.   5) |        |                    |  | nd Securit<br>Benefic | ies For<br>cially (D)<br>Following (I) (   |  | Direct<br>Indirect<br>str. 4)                       | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)  |  |           |  |
|  |  |                                      |   |   |   | Code | v                 | Amount | nt (A) or (D)      |  | Transa                | action(s)<br>3 and 4)  |  |   | (111511.4)   |  |           |  |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |                                      |   |   |   |      |                   |        |                    |  |                       |  |  |   |  |  |           |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)            | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | rcise (Month/Day/Year)<br>of<br>tive | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |   | 4.<br>Transaction<br>Code (Instr<br>8)                      |      | n of              |        | Expiration Date    |  |                       | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Secu<br>(Instr. 3 and 4)   |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | Owner<br>Form:<br>Direct<br>or Ind<br>(I) (Ins | Ownership | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|  |  |                                      |   | С   | ode   | v    | (A)               | (D)    | Date<br>Exercisabl |  | xpiration<br>ate      | Title  | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |           |  |
| Stock<br>Equivalent<br>Units                                   | \$0 <sup>(1)</sup>   | 12/31/2014                           |   |   | A   |      | 527               |        | (1)                |  | (1)                   | Common<br>stock  | 527                                    | \$65.44   | 11,963 <sup>(2)</sup>  | )  | D         |  |

## **Explanation of Responses:**

- 1. Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 2. Balance includes stock equivalent units acquired pursuant to a dividend equivalent reinvestment feature.

Steven L. Scrogham, attorney-01/05/2015 in-fact for Edward M. Liddy

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.